Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
| Press Release Montrouge, France, April 5, 2017 |
DBV Technologies to Attend the 10th Kempen Life Sciences Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Senior Vice President, Strategy, will host investor meetings during the 10th Kempen Life Sciences Conference on Wednesday, April 19, 2017, at the Kempen & Co offices in Amsterdam, Netherlands.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
[email protected]
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
[email protected]
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
[email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/fae7f813-7f1f-41c5-b96f-08b9df9f1ec2
